Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches

Area of Science:

• Pulmonology
• Toxicology
• Immunology

Background:

• Drug-induced interstitial lung disease (DILD) is a significant clinical concern with diverse presentations, from mild infiltrates to acute respiratory distress syndrome.
• DILD pathogenesis involves direct drug toxicity and immune-mediated responses, often T cell-dependent, leading to lung injury.
• Accurate diagnosis of DILD is challenging, frequently relying on exclusion, and identifying the culprit drug is crucial for preventing recurrence.

Purpose of the Study:

• To explore the diagnostic potential of cell-mediated immunity tests for DILD.
• To review current literature on diagnostic methods for drug-induced interstitial lung disease.
• To assess the utility of drug-induced lymphocyte stimulation test (DLST) and leukocyte migration test (LMT) in DILD diagnosis.

Main Methods:

• Literature review of diagnostic approaches for DILD.
• Exploration of cell-mediated immunity assays, including DLST and LMT, using peripheral blood samples.
• Analysis of the role of drug re-exposure and lymphocyte sensitization tests in confirming DILD.

Main Results:

• Drug-induced interstitial lung disease involves both direct toxicity and immune mechanisms, with T cells playing a key role.
• Current diagnostic methods for DILD are often indirect, with drug re-challenge posing risks.
• Tests assessing cell-mediated immunity, like DLST and LMT, can detect drug-sensitized T cells but lack a definitive role in DILD diagnosis.

Conclusions:

• Identifying the causative drug is essential for managing DILD and preventing further harm.
• While DLST and LMT show promise in detecting drug-sensitized lymphocytes, their definitive role in DILD diagnosis requires further investigation.
• Further research into cell-mediated immunity tests may improve the diagnostic accuracy and management of drug-induced interstitial lung disease.